Because CI therapies, including the PD-1 antibodies, target the immune system rather than the tumor, CI antibodies can theoretically be used to treat many forms of cancer and this notion has been successfully translated into the clinic with regard to anti-PD-1. The gene discussed is PDCD1; the disease is neoplasm.